The Only Futures Trading Guide You’ll Ever Need
Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.
Download your FREE Technical Analysis Trading Guide Today!
David P. Luci, insider at Acurx Pharmaceuticals
David P. Luci Insider Alerts

Get notified the next time David P. Luci buys or sells Acurx Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

David P. Luci Insider Information

Mr. Luci is our co-founder and President & CEO.  Prior to our IPO, Mr. Luci served as Managing Partner and Director since February 2018. Previously, Mr. Luci was the President and Chief Executive Officer of Dipexium Pharmaceuticals (Nasdaq: DPRX), a pharmaceutical company focused on antibiotic drug development, from February 2010 until its sale to PLx Pharma Inc. (Nasdaq: PLXP) in a merger valued at $69 million in April 2017. From February 2009 to January 2010, Mr. Luci served as a member of the board of directors of Abeona Therapeutics, where he also served as Chairman of the Audit Committee and Chairman of the Compensation Committee as well as serving in a consulting capacity following the acquisition of MacroChem. From December 2007 through February 2009, Mr. Luci served as a member of the board of directors and President of MacroChem. Prior to that, Mr. Luci served as Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary of Bioenvision, Inc. (or Bioenvision), an international biopharmaceutical company focused upon the development, marketing and commercialization of oncology products and product candidates.

Mr. Luci began his career with Ernst & Whinney LLP (now Ernst &Young LLP) in New York as a certified public accountant working in the Healthcare Practice Group. He later practiced corporate law at Paul Hastings LLP in New York, where his practice encompassed all aspects of public and private mergers and acquisitions, corporate finance, restructurings and private equity transactions, with a core focus in the healthcare industry. Mr. Luci graduated from Bucknell University with a degree as a Bachelor of Science in Business Administration with a concentration in Accounting and graduated from Albany Law School of Union University where he served as Managing Editor of the Journal of Science & Technology. Mr. Luci became a certified public accountant in the State of Pennsylvania in 1990 (inactive) and is a member of the New York State Bar Association. Mr. Luci was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.

How old is David P. Luci?

Mr. Luci is currently 54 years old. There are 1 older executives and no younger executives at Acurx Pharmaceuticals. The oldest executive at Acurx Pharmaceuticals is Mr. Robert J. DeLuccia, Co-Founder & Exec. Chairman, who is 75 years old. Learn More.

How do I contact David P. Luci?

The corporate mailing address for Mr. Luci and other Acurx Pharmaceuticals executives is , , . Acurx Pharmaceuticals can also be reached via phone at 917-533-1469 and via email at [email protected]

Has David P. Luci been buying or selling shares of Acurx Pharmaceuticals?

During the past quarter, David P. Luci has bought $24,960.00 in shares of Acurx Pharmaceuticals stock. Most recently, on Friday, November 19th, David P. Luci bought 5,200 shares of Acurx Pharmaceuticals stock. The stock was acquired at an average cost of $4.80 per share, with a total value of $24,960.00.

Who are Acurx Pharmaceuticals' active insiders?

Acurx Pharmaceuticals' insider roster includes Robert DeLuccia (Director), and David Luci (CEO).

Are insiders buying or selling shares of Acurx Pharmaceuticals?

In the last twelve months, Acurx Pharmaceuticals insiders bought shares 3 times. They purchased a total of 15,395 shares worth more than $74,605.84. The most recent insider tranaction occured on November, 23rd when Director Carl Sailer bought 5,161 shares worth more than $24,979.24.

Information on this page was last updated on 11/23/2021.

David P. Luci Insider Trading History at Acurx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Buy5,200$4.80$24,960.00View SEC Filing Icon  
See Full Table

David P. Luci Buying and Selling Activity at Acurx Pharmaceuticals

This chart shows David P Luci's buying and selling at Acurx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acurx Pharmaceuticals Company Overview

Acurx Pharmaceuticals logo
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Read More

Today's Range

Now: $4.15
Low: $4.15
High: $4.51

50 Day Range

MA: $4.90
Low: $4.09
High: $5.64

2 Week Range

Now: $4.15
Low: $3.71
High: $8.74

Volume

51,773 shs

Average Volume

48,708 shs

Market Capitalization

$42.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Only Futures Trading Guide You’ll Ever Need
Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets.
Download your FREE Technical Analysis Trading Guide Today!